Breast cancer claims approximately 670,000 lives each year, making it a significant global health concern. According to data from the World Health Organization (WHO), breast cancer was the most prevalent cancer among women in 157 out of 185 countries in 2022. With over 2 million women being diagnosed with breast cancer annually, early detection and effective treatment are crucial in combating this deadly disease. The US Food and Drug Administration (FDA) has approved Kisqali, also known as ribociclib, for use in conjunction with hormone therapy for early-stage breast cancer patients. This approval provides a new treatment option for patients concerned about the recurrence of cancer. Ribociclib, a selective cyclin-dependent kinase inhibitor, works by targeting proteins that can promote the rapid growth and division of cancer cells. Administered orally in the form of a pill, Kisqali is prescribed for a three-week cycle followed by a one-week break, to be continued over a three-year period. It can be taken with or without food, with a recommended daily dose of 400 mg.Kisqali: Potential Side Effects

Common side effects of Kisqali medication include decreased white blood cell count, known as neutropenia, which can weaken the body's ability to fight infections due to low levels of neutrophils in the blood. Additionally, Kisqali may also cause liver-related complications and interstitial lung disease or pneumonitis.

Breast Cancer: Warning Signs to Recognize Early